Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 18/20 | 0.68 |
| ▸ | RCOR1 | Q9UKL0 | 7/20 | 0.67 |
| ▸ | MAOA | P21397 | 12/20 | 0.44 |
| ▸ | MAOB | P27338 | 12/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15767794 | 0.81 | KDM1A (0.96) | KDM1ARCOR1MAOAMAOB | |
| SCHEMBL15767793 | 0.81 | KDM1A (0.96) | KDM1ARCOR1MAOAMAOB | |
| SCHEMBL15780112 | 0.81 | KDM1A (0.96) | KDM1ARCOR1MAOAMAOB | |
| SCHEMBL15766931 | 0.81 | KDM1A (1.00) | KDM1AMAOAMAOB | |
| SCHEMBL15780140 | 0.81 | KDM1A (1.00) | KDM1AMAOAMAOB | |
| SCHEMBL15766930 | 0.81 | KDM1A (1.00) | KDM1AMAOAMAOB | |
| SCHEMBL17231241 | 0.76 | KDM1A (0.97) | KDM1ARCOR1MAOAMAOB | |
| SCHEMBL15777612 | 0.76 | KDM1A (0.97) | KDM1ARCOR1MAOAMAOB | |
| SCHEMBL15777611 | 0.76 | KDM1A (0.97) | KDM1ARCOR1MAOAMAOB | |
| Hydrochloric Acid SCHEMBL17223512 | 0.75 | KDM1A (1.00) | KDM1ARCOR1MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8268894-B2 | Compositions and methods for the treatment of infectious diseases | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2012-09-18 | — | — | US | disclosed |
| US-8202910-B2 | Compositions and methods for treatment of infectious disease | SEQUELLA, INC. (US) | 2012-06-19 | — | — | US | disclosed |
| US-20110118307-A1 | Compositions and methods for the treatment of infectious diseases | GOVERNMENT OF THE UNITED STATES OF AMERICA REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2011-05-19 | — | — | US | disclosed |
| US-7842729-B2 | Anti tubercular drug: compositions and methods | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2010-11-30 | — | — | US | disclosed |
| US-7456222-B2 | Anti tubercular drug: compositions and methods | SEQUELLA, INC. (US) | 2008-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118307-A1 | Compositions and methods for the treatment of infectious diseases | TERT, C5, ELANE | KDM1A 2503/4885RCOR1 3591/4885MAOA 1858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.